Genfit (GNFT) H.C. Wainwright 28th Annual Global Investment Conference presentation summary

Strategic partnerships and financial position

• Maintains strong cash position of €136.1M as of 1Q26, with cash runway projected beyond 2028 and no debt overhang.

• Partnership with Ipsen for elafibranor in PBC has yielded €105.5M in milestones and €34M in royalties to date, with potential for up to €360M in milestones and double-digit royalties.

• Royalty financing agreement with HCRX provided €160M, with milestones excluded from the deal.

Commercial and clinical progress of elafibranor (Iqirvo)

• Iqirvo launched in 2024 for PBC, achieving strong sales growth and upgraded peak sales guidance to €1bn.

• ELSPIRE Phase IIIb study showed 85% ALP normalization in PBC patients, significantly expanding the addressable market.

• Phase 3 trial initiated in PSC, targeting a market with no approved therapies and data readout expected in 2031.

Diagnostic innovation and market opportunity in MASH

• Non-invasive diagnostic technology (NIS2+) validated by leading consortia and included in major clinical guidelines.

• NASHnext test reimbursed by Medicare as of August 2026, supporting broader adoption and future private insurer coverage.

• U.S. laboratory market for NIS2+ projected to reach $1.5B peak annual revenue by 2033, driven by increased diagnosis and monitoring.